Motley Fool Money 2 Blue Chips Under Pressure
Jan 24, 2023
Asit Sharma, a senior analyst at Motley Fool, shares insights into Johnson & Johnson's recent profit drop and its promising balance of pharma and medtech. He also discusses 3M's ongoing challenges and the potential benefits of shifting towards consumer solutions. Alison Southwick answers listener questions on retirement savings, emphasizing the importance of diversification and risk management. They explore opportunities in undervalued stocks and suggest allocating part of your portfolio to international markets for better growth.
AI Snips
Chapters
Transcript
Episode notes
J&J Split and Kenvue
- The upcoming split of Johnson & Johnson will separate its consumer health segment, Kenvue.
- The remaining company, focused on pharma and medtech, is expected to remain strong.
J&J Q4 and Future Outlook
- Johnson & Johnson's Q4 profits fell 25% partly due to reduced COVID-19 vaccine demand.
- The company anticipates 5% sales growth next year, driven by pharma and medtech.
3M's Diverse Business
- 3M’s diverse business segments, from consumer adhesives to healthcare, are impacted by various economic factors.
- This makes it hard for them to achieve high growth when only some sectors are doing well.